Amarin | AMRN - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 7.61B 2.04B 2026-06
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amarin USD -852K 7.26M 2025-12
AstraZeneca USD 4.81B 894M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
DBV Technologies USD -47.4M 14.24M 2026-03
GlaxoSmithKline GBP 2.68B 532M 2026-06
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114M 21M 2026-06
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06